EUCTR2019-004186-40-GR进行中（未招募）1 期
A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients currently hospitalized for acute decompensated heart failure (ADHF)
- •-Patients must be hemodynamically stable, as assessed by the investigator
- •-Men must agree to follow specific methods of contraception, if applicable, while participating in the trial
- •-Women participants must have documented proof that they are not of childbearing potential
- •- A female participant is eligible to participate if she is not pregnant or breastfeeding, and is not a WOCBP.
- •- No healthy patients, only subjects
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 47
排除标准
- •-Acute cardiovascular condition other than heart failure (HF) decompensation
- •-Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization
- •-Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization
- •-Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis
研究者
相似试验
进行中（未招募）
1 期
The metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations who have notprogressed after docetaxel therapymetastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001205-73-ITIMPACT Therapeutics Inc.165
尚未招募
Unknown
Effectiveness and Safety of Cg-A1 Peptide in Patients with Muscle AtrophyCTRI/2024/01/061919Caregen.Co., Ltd
进行中（未招募）
3 期
Study to Assess the Effects of Deglusterol on Fasting Glucose and Other Cardiometabolic Risk Factors in type 2 diabetes mellitus patients who are on Metformin + gliptin combination therapy.CTRI/2024/01/062047Caregen Co., Ltd.
进行中（未招募）
3 期
Study to Assess the Effects of Deglusterol on Type 2 Diabetes Mellitus.CTRI/2023/07/054724Caregen Co., Ltd.
进行中（未招募）
1 期
The metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations who have not progressed after docetaxel therapymetastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001205-73-BEIMPACT Therapeutics, Inc.660